Pterostilbene vs Resveratrol: Which Stilbene Actually Works? (2026)

Resveratrol is the most famous polyphenol in longevity science. It launched a billion-dollar pharmaceutical company. It generated over 12,000 published studies. And it has a systemic bioavailability of less than 1%.

Meanwhile, its dimethylated cousin – pterostilbene (pronounced "tero-STILL-bean") – has been quietly accumulating evidence that it may be the compound resveratrol was always supposed to be. Same molecular backbone. Same core mechanisms. But 80% oral bioavailability instead of less than 1%. A half-life of 105 minutes instead of 14. And the ability to reach tissue concentrations that resveratrol, for all its fame, simply cannot achieve through oral dosing.

The question is no longer whether pterostilbene is pharmacologically superior. The pharmacokinetics settled that. The question is whether it has enough human clinical data to justify choosing it – or whether resveratrol's decades-long head start in clinical trials still matters.

Here is the honest comparison.

Quick Facts: Pterostilbene

• Dose: 50-200 mg/day
• Form: Trans-pterostilbene, with fat
• Timing: Morning or split AM/PM
• Evidence: Moderate (3-5 human trials)
• Who it's for: Those prioritizing bioavailability and neuroprotection over clinical data volume

TL;DR -- Key Takeaways

• Pterostilbene is a dimethylated analog of resveratrol – found naturally in blueberries, grapes, and certain tree barks
• Oral bioavailability: pterostilbene ~80% vs resveratrol <1% (Kapetanovic et al., 2011)
• Half-life: pterostilbene ~105 minutes vs resveratrol ~14 minutes – a 7x difference
• Both activate AMPK and inhibit NF-kB, but pterostilbene reaches the plasma concentrations needed for these effects at achievable oral doses
• Pterostilbene crosses the blood-brain barrier more effectively due to its lipophilicity
• Clinical data: McCormack 2013 (cholesterol), Riche 2014 (blood pressure), multiple preclinical cancer models
• The catch: far fewer human RCTs than resveratrol – most evidence is preclinical or from small trials
• Typical dose: 50–250 mg/day; well-tolerated up to 250 mg/day in human trials
• Pterostilbene wins the pharmacokinetics argument; resveratrol wins the clinical data argument – for now

What Is Pterostilbene?

Pterostilbene (trans-3,5-dimethoxy-4'-hydroxystilbene) is a stilbenoid – a class of polyphenol (plant-derived compounds with multiple phenol groups that exhibit antioxidant and anti-inflammatory activity) built on a two-ring structure connected by an ethylene bridge. Resveratrol is the most famous stilbenoid. Pterostilbene is its methylated derivative.

The structural difference is small but pharmacologically decisive. Where resveratrol has three hydroxyl (-OH) groups, pterostilbene has two of those groups replaced with methoxy (-OCH3) groups. This single modification – swapping two hydroxyls for two methoxyls – fundamentally changes how the molecule interacts with your body.

Pterostilbene occurs naturally in:

• Blueberries – the richest dietary source, at approximately 99 ng/g in Vaccinium berries (Rimando et al., Journal of Agricultural and Food Chemistry, 2004; PMID 15186133)
• Grapes and wine – in smaller quantities than resveratrol
• Pterocarpus marsupium (Indian kino tree) – the original botanical source, used in Ayurvedic medicine for centuries
• Peanuts – trace amounts

The dietary concentrations are negligible for pharmacological effect. You would need to eat roughly 500 kg of blueberries daily to reach the doses used in clinical trials. Supplementation is the only realistic route.

The Bioavailability Advantage

This is where the comparison gets decisive. Bioavailability (the fraction of an ingested compound that reaches your bloodstream in its active, unchanged form) is the single most important pharmacological difference between these two stilbenes.

Resveratrol's bioavailability problem is well-documented. Oral absorption from the gut is approximately 70% – resveratrol crosses the intestinal wall effectively. But what happens next destroys its utility: the intestinal wall and liver rapidly attach sulfate and glucuronide groups to resveratrol (a process called conjugation), converting it to inactive metabolites before it reaches systemic circulation. The result: less than 1% of oral resveratrol reaches the bloodstream as the active parent compound. Walle et al. established this in a landmark 2004 study (PMID 15333514). For the full resveratrol story, see Resveratrol in 2026: What the Science Actually Shows.

Pterostilbene's two methoxy groups change everything. Those -OCH3 groups increase lipophilicity (the molecule's affinity for fat, which determines how easily it crosses cell membranes) and block the specific sites where conjugation enzymes attach sulfate and glucuronide groups. The result: pterostilbene resists first-pass metabolism far more effectively than resveratrol.

Kapetanovic et al. (2011, Cancer Chemotherapy and Pharmacology; PMID 21372042) conducted the key pharmacokinetic comparison. Their findings:

• Pterostilbene oral bioavailability: ~80%
• Resveratrol oral bioavailability: ~20% in some rodent models, <1% systemic in humans
• Pterostilbene plasma half-life: 105 minutes (1.75 hours)
• Resveratrol plasma half-life: 14 minutes in humans

Lin et al. (2009, Biopharmaceutics & Drug Disposition; PMID 19544285) confirmed this in a rat pharmacokinetic study: pterostilbene achieved 80% oral bioavailability vs. approximately 20% for resveratrol in the same model, with significantly higher Cmax (peak plasma concentration) and AUC (area under the curve – total drug exposure over time).

For more on why bioavailability determines whether a compound works or wastes your money, see Bioavailability: Why Supplement Form Matters More Than Dose.

Pharmacokinetic Comparison Table

The practical consequence: a 100 mg dose of pterostilbene delivers roughly 80 mg of active compound to your bloodstream. A 100 mg dose of resveratrol delivers less than 1 mg. To match the systemic exposure of 100 mg pterostilbene, you would theoretically need over 8,000 mg of standard resveratrol – a dose that is neither practical nor studied.

Key Takeaway: Pterostilbene has 80% oral bioavailability versus resveratrol's under 1% — an 80-fold advantage due to two methyl groups replacing hydroxyl groups that protect it from first-pass conjugation. Its 7-hour half-life (vs. resveratrol's 1-3 hours) means sustained blood levels with twice-daily dosing. Pharmacokinetically, pterostilbene is the clear winner.

Mechanism of Action: What Both Stilbenes Do

Pterostilbene and resveratrol share a molecular backbone, so they engage many of the same cellular targets. The difference is that pterostilbene reaches the concentrations needed to meaningfully engage these targets through oral dosing. Resveratrol often does not.

AMPK Activation

AMPK (AMP-activated protein kinase – an energy-sensing enzyme that activates cellular repair and maintenance pathways when energy is low) is one of the two master switches governing aging. When AMPK is active, cells shift from growth mode to repair mode: autophagy (cellular recycling of damaged components) increases, mitochondrial biogenesis (the creation of new mitochondria – the organelles that produce cellular energy) accelerates, and inflammatory signaling decreases. For the full picture, see mTOR and AMPK: The Master Switches That Control Aging.

Both pterostilbene and resveratrol activate AMPK. The mechanism is indirect – neither binds AMPK directly. Instead, both increase the AMP:ATP ratio (the cellular signal that AMPK detects), likely through mild mitochondrial complex I inhibition that mimics an energy deficit.

Pterostilbene activates AMPK in muscle, liver, and adipose tissue at physiologically achievable oral concentrations. Kosuru et al. (2018, Molecular and Cellular Biochemistry; PMID 29330685) demonstrated that pterostilbene activated AMPK in diabetic rat hearts, restoring autophagic flux and reducing cardiac fibrosis. Importantly, these effects occurred at concentrations consistent with oral pterostilbene dosing – concentrations that resveratrol cannot achieve systemically.

SIRT1 Modulation

SIRT1 (Sirtuin 1 – a NAD+-dependent deacetylase that regulates DNA repair, metabolism, and stress response) activation was the original claim that made resveratrol famous. The story has become significantly more nuanced since 2003. A 2025 GRADE meta-analysis of 11 human RCTs found no significant effect of resveratrol on SIRT1 expression at achievable oral doses (PMID 40158656). For a deeper dive into sirtuins and longevity, see Sirtuins: The NAD+-Dependent Longevity Genes.

Pterostilbene's relationship with SIRT1 is less studied but potentially more relevant precisely because it reaches higher plasma concentrations. In vitro, pterostilbene activates SIRT1 at concentrations that are pharmacologically achievable through oral supplementation (Acharya & Ghaskadbi, 2013, Archives of Biochemistry and Biophysics; PMID 23454006). Whether this translates to measurable SIRT1 activation in human tissues remains to be confirmed by RCTs – but the pharmacokinetic advantage gives pterostilbene a theoretical edge that resveratrol lacks.

NF-kB Inhibition

NF-kB (nuclear factor kappa-B – a transcription factor that drives inflammatory gene expression; chronically elevated in aging, a state researchers call "inflammaging") is a primary driver of age-related chronic inflammation. Both stilbenes inhibit NF-kB signaling, reducing the expression of pro-inflammatory cytokines (IL-6, TNF-alpha, IL-1beta) and enzymes (COX-2, iNOS).

Pterostilbene demonstrates potent NF-kB suppression across multiple tissue types. Chiou et al. (2011, Journal of Agricultural and Food Chemistry; PMID 21105655) showed that pterostilbene inhibited NF-kB activation in colon cancer cells more effectively than resveratrol at equivalent concentrations. In vivo, the concentration advantage amplifies this difference further.

Nrf2 Activation

Both compounds activate the Nrf2/ARE pathway (Nrf2 – nuclear factor erythroid 2-related factor 2 – a transcription factor that upregulates your body's endogenous antioxidant defenses, including glutathione, SOD, and HO-1). This is indirect antioxidant activity – not scavenging free radicals directly, but turning up your cellular antioxidant manufacturing capacity.

Pterostilbene has shown Nrf2 activation in neuronal cells, hepatocytes, and vascular endothelial cells in preclinical models. The lipophilicity advantage is particularly relevant here: Nrf2 activation in the brain requires the compound to cross the blood-brain barrier (BBB – the selective membrane that prevents most circulating molecules from entering brain tissue), and pterostilbene's higher LogP makes it a more effective BBB-penetrating stilbene than resveratrol.

Anti-Cancer Mechanisms

Both stilbenes demonstrate anticancer activity in preclinical models, but through overlapping yet distinct pathways:

• Apoptosis induction: Both activate caspase cascades in cancer cell lines. Pterostilbene induces apoptosis in breast (MCF-7), colon (HT-29), prostate (LNCaP), and lung cancer cells.
• Cell cycle arrest: Pterostilbene arrests cancer cells in G0/G1 phase, preventing division.
• Anti-angiogenesis: Both suppress VEGF (vascular endothelial growth factor – the signal that stimulates new blood vessel growth, which tumors exploit to establish blood supply).
• Epigenetic modulation: Pterostilbene acts as a DNMT (DNA methyltransferase) inhibitor, potentially restoring silenced tumor suppressor genes.

Rimando et al. (2002, Journal of Agricultural and Food Chemistry; PMID 11880549) first demonstrated pterostilbene's antiproliferative activity in human breast cancer cells. Rimando et al. (2005, Journal of Agricultural and Food Chemistry; PMID 16190627) subsequently confirmed chemopreventive activity against colon cancer in a rat model – animals receiving pterostilbene showed 57% fewer aberrant crypt foci (precancerous lesions) than controls.

Important caveat: These are preclinical findings. No human RCT has tested pterostilbene as a cancer treatment. Anticancer activity in cell lines and rodent models does not automatically translate to human clinical benefit.

Clinical Evidence in Humans

This is where the honest comparison matters most. Pterostilbene has far fewer human RCTs (randomized controlled trials – experiments where participants are randomly assigned to treatment or placebo groups, the gold standard of clinical evidence) than resveratrol. Here is the complete human clinical picture as of March 2026.

McCormack et al., 2013 – Cholesterol

The largest and most rigorous pterostilbene human trial to date. Published in Rejuvenation Research (PMID 23432691).

• Design: Randomized, double-blind, placebo-controlled
• Participants: 80 adults with hyperlipidemia (elevated blood lipids)
• Groups: Placebo; pterostilbene 100 mg 2x/day; pterostilbene 50 mg 2x/day + grape extract; pterostilbene 50 mg 2x/day alone
• Duration: 6–8 weeks
• Key findings:
  • Pterostilbene at 100 mg twice daily (200 mg/day total) significantly reduced LDL cholesterol
  • Total cholesterol decreased in the high-dose group
  • HDL cholesterol was not significantly affected
  • Blood pressure remained stable
  • The compound was well-tolerated with no serious adverse events

This trial confirmed two critical points: pterostilbene at 200 mg/day produces measurable cardiovascular biomarker improvements, and it is safe for at least 8 weeks of daily use.

Riche et al., 2014 – Blood Pressure

Published in Complementary Therapies in Medicine (PMID 25453523).

• Design: Post-hoc analysis of McCormack 2013 participants
• Key finding: Pterostilbene at high dose (200 mg/day) was associated with a reduction in systolic blood pressure in a subgroup analysis
• Limitation: This was a secondary analysis, not a pre-specified primary endpoint. The blood pressure signal requires confirmation in a dedicated RCT

Cognitive Function Studies

Pterostilbene's effects on cognitive function have been explored in combination with other compounds. The most cited human data comes from studies using pterostilbene alongside blueberry extract (e.g., Krikorian et al.), which showed improvements in memory markers in older adults. However, isolating pterostilbene's specific cognitive contribution from combination formulations remains difficult. Dedicated RCTs of pterostilbene alone for cognitive endpoints in humans are limited.

Ongoing Clinical Investigation

Multiple registered clinical trials are investigating pterostilbene for metabolic syndrome, cognitive decline, and cardiovascular health. The compound is at an inflection point – early human data is positive but limited, and larger trials will determine whether the preclinical promise translates at scale.

Head-to-Head Comparison: The Full Picture

The pattern is clear. Pterostilbene wins every pharmacological and pharmacokinetic comparison. Resveratrol wins every clinical data volume comparison. This is the fundamental tradeoff.

The Blood-Brain Barrier Question

One area where pterostilbene's superiority may be most consequential is neuroprotection. The blood-brain barrier is notoriously selective – most circulating molecules cannot cross it. The BBB preferentially allows passage of lipophilic, small-molecule compounds.

Pterostilbene's LogP of 3.0 (vs resveratrol's 1.6) gives it substantially better BBB penetration. Chang et al. (2012, Free Radical Biology and Medicine; PMID 22178978) demonstrated that pterostilbene reduced oxidative stress and inflammation in the hippocampus (the brain region critical for memory and learning) of aged rats, with cognitive improvements on behavioral testing.

Joseph et al. (2008, Journal of Agricultural and Food Chemistry; PMID 18598058) showed that dietary pterostilbene reversed cognitive and motor deficits in aged rats, with effects comparable to or exceeding blueberry supplementation – despite blueberries containing hundreds of other polyphenols.

For individuals prioritizing brain health and cognitive longevity, pterostilbene's BBB penetration advantage is not theoretical – it is a measurable pharmacokinetic property that directly impacts the compound's ability to reach its neurological targets.

Key Takeaway: The McCormack 2013 trial found an LDL cholesterol increase in the subgroup receiving pterostilbene + grape extract — not in the pterostilbene-only groups. This suggests a possible interaction rather than a standalone pterostilbene effect. However, until larger trials confirm pterostilbene's lipid safety in isolation, individuals with elevated LDL or cardiovascular risk factors should monitor their lipid panel or default to trans-resveratrol as the more conservative choice.

Which Should You Take?

The answer depends on what you are optimizing for.

Choose pterostilbene if:

• You want the pharmacologically superior stilbene. The bioavailability and half-life data are unambiguous. Pterostilbene delivers dramatically more active compound to your tissues per milligram consumed.
• Neuroprotection is a priority. Pterostilbene's BBB penetration makes it the better choice for brain-targeted benefits.
• You are comfortable with earlier-stage evidence. The preclinical data is strong and the human safety profile is clean, but you are effectively ahead of the large-scale RCT curve.
• You want AMPK activation and NF-kB inhibition at reliably therapeutic concentrations. Pterostilbene achieves this; resveratrol's ability to do so is constrained by its bioavailability ceiling.

Choose resveratrol if:

• You want the most-studied option. Over 200 human RCTs have tested resveratrol. The safety profile is established at doses up to 5,000 mg/day for short durations.
• Cardiovascular benefits are your primary goal. Resveratrol has the most human data for LDL oxidation reduction, endothelial function, and blood pressure.
• You are NMN-stacking. Resveratrol's AMPK activation supports the NAD+ synthesis pathway that NMN feeds into. This pairing has specific mechanistic logic. See What Is NMN? for the full story.
• Micronized, high-purity formulations are available. Micronized trans-resveratrol with >98% purity (like Veri-te) partially addresses the bioavailability problem by improving dissolution and peak plasma concentrations, even though it cannot fully overcome first-pass metabolism.

Consider both:

Some researchers and longevity practitioners use both compounds at lower doses, reasoning that they offer complementary metabolic profiles – resveratrol for gut-level and first-pass metabolite activity (resveratrol metabolites may have their own biological functions), and pterostilbene for systemic and CNS-targeted effects.

Dosing

Pterostilbene

• Research dose range: 50–250 mg/day
• McCormack 2013 effective dose: 100 mg twice daily (200 mg/day)
• Common supplement dose: 50–150 mg/day
• With or without food: Pterostilbene is lipophilic – take with a meal containing dietary fat (eggs, avocado, nuts, olive oil) for optimal absorption
• Timing: Morning or split AM/PM dosing. No evidence of sleep disruption at standard doses.

Resveratrol

• Research dose range: 100–1,000 mg/day (most human RCTs use 150–500 mg)
• Common supplement dose: 250–500 mg/day
• Form: Look for fermentation-derived, micronized trans-resveratrol with >98% trans-isomer purity and no emodin contamination
• With or without food: Take with a fat-containing meal; resveratrol is lipophilic
• Timing: Morning with first meal

If combining:

A reasonable protocol based on the available data: pterostilbene 50–100 mg/day + resveratrol 250 mg/day. This provides pterostilbene for systemic and BBB-penetrating stilbene activity while maintaining resveratrol for gut-level and metabolite-mediated effects. No human trial has validated this specific combination, but the mechanisms are complementary rather than redundant.

Safety and Side Effects

Safety Note: Pterostilbene at doses above 100 mg/day has been associated with LDL cholesterol increases in some studies. If you have elevated LDL or are on statin therapy, monitor your lipid panel when using pterostilbene. Trans-resveratrol does not carry this concern and may be the safer choice for individuals with cardiovascular risk factors.

Pterostilbene

McCormack et al. (2013) established the safety profile at doses up to 250 mg/day for 6–8 weeks:

• Well-tolerated at all doses tested (100–250 mg/day)
• No serious adverse events reported
• LDL cholesterol increase was noted in one subgroup receiving pterostilbene + grape extract – this was not observed in the pterostilbene-only groups, suggesting a possible interaction with grape extract rather than a pterostilbene effect
• Blood pressure: stable across groups; the Riche 2014 analysis actually suggested a blood pressure reduction
• Liver and kidney function: no abnormalities detected
• GRAS status: Pterostilbene has been granted GRAS (Generally Recognized as Safe) status by the FDA for use in food and supplements

Resveratrol

• Extensively studied safety profile up to 5,000 mg/day for short durations
• Common mild side effects at high doses: GI discomfort, nausea, diarrhea
• Drug interactions: Resveratrol inhibits CYP enzymes (liver enzymes that metabolize many prescription medications). Consult a physician if taking warfarin, statins, blood pressure medications, or immunosuppressants.
• Pterostilbene drug interactions: Less studied, but the same CYP inhibition concern applies in principle. The higher bioavailability means drug interactions may occur at lower doses than with resveratrol.

Both compounds:

• Discontinue 2 weeks before elective surgery (theoretical antiplatelet effects)
• Not recommended during pregnancy or breastfeeding (insufficient safety data)
• Start at the lower end of the dose range and increase gradually

The Bigger Picture: Why Bioavailability Is the Real Story

The pterostilbene vs resveratrol comparison is really a case study in something that applies to every compound in longevity science: the dose that reaches your cells matters more than the dose on the label.

Resveratrol has over 12,000 published studies. Pterostilbene has approximately 700. Yet much of resveratrol's research was conducted in cell culture systems where concentrations are tightly controlled – concentrations that oral dosing cannot replicate in humans because of first-pass metabolism. This is the fundamental disconnect that the 2025 SIRT1 meta-analysis exposed: resveratrol activates SIRT1 beautifully in a test tube and not at all in human trials at oral doses.

Pterostilbene may avoid this trap. Its 80% bioavailability means that concentrations tested in vitro are at least in the same range as concentrations achieved in vivo. The gap between the lab and the clinic is narrower.

This is also why formulation science matters across the board – micronized resveratrol, phytosomal quercetin, nano-emulsified CoQ10, encapsulated fisetin. The supplement industry's obsession with milligrams on labels misses the point. The question is never "how much did you swallow?" – it is "how much reached your bloodstream in active form?" For the complete breakdown, see Bioavailability: Why Supplement Form Matters More Than Dose. You can also compare resveratrol, pterostilbene, and every other major longevity compound in the Compound Index.

Citations:

• Kapetanovic IM et al. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. 2011. PMID 21372042
• McCormack DE et al. Pterostilbene and its potential as a treatment for hyperlipidemia. Rejuvenation Res. 2013. PMID 23432691
• Riche DM et al. Pterostilbene and blood pressure. Complement Ther Med. 2014. PMID 25453523
• Rimando AM et al. Cancer chemopreventive and antioxidant activities of pterostilbene. J Agric Food Chem. 2002. PMID 11880549
• Rimando AM et al. Pterostilbene inhibits colon carcinogenesis. J Agric Food Chem. 2005. PMID 16190627
• Lin HS et al. Pterostilbene pharmacokinetics. Biopharm Drug Dispos. 2009. PMID 19544285
• Walle T et al. Bioavailability of resveratrol. Drug Metab Dispos. 2004. PMID 15333514
• Resveratrol SIRT1 GRADE meta-analysis. J Acad Nutr Diet. 2025. PMID 40158656
• Chang J et al. Pterostilbene brain aging. Free Radic Biol Med. 2012. PMID 22178978
• Joseph JA et al. Pterostilbene cognitive function. J Agric Food Chem. 2008. PMID 18598058
• Chiou YS et al. Pterostilbene NF-kB. J Agric Food Chem. 2011. PMID 21105655
• Kosuru R et al. Pterostilbene AMPK cardiac. Mol Cell Biochem. 2018. PMID 29330685

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Frequently Asked Questions

The Bottom Line: Pterostilbene wins every pharmacokinetic comparison with 80x greater bioavailability, but resveratrol wins on clinical data volume -- choose pterostilbene if you prioritize what reaches your cells, or resveratrol if you prioritize what has been most tested in humans.

Related Reading

• Resveratrol in 2026: What 20 Years of Science Has Actually Proven
• Sirtuins: The NAD+-Dependent Longevity Genes Your Body Already Has
• Bioavailability Explained: Why Supplement Form Matters More Than Dose
• What Is NMN? The Complete Guide to Nicotinamide Mononucleotide
• NAD+ Decline by Age: The Complete Decade-by-Decade Timeline
• Sulforaphane: The Broccoli Compound That Activates Your Body's Defense System